Gadopiclenol is a gadolinium-based contrast agent (GBCA) used with contrasted magnetic resonance imaging (MRI) to detect and visualize lesions and abnormal vascularity. In 2006, the use of GBCAs was associated with the development of nephrogenic systemic fibrosis (NSF), a rare disorder characterized by the thickening and hardening of skin and subcutaneous tissues.
- Mechanism
- Curator reviewed · 2 references
Gadopiclenol is a macrocyclic non-ionic complex of gadolinium and a paramagnetic molecule that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body. Its use in magnetic resonance imaging (MRI) allows to selectively increase contrast in tissues where gadopiclenol accumulates.
- Primary indication
- Gadopiclenol is indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated...Curator reviewed · 2 structured indications
- Formula / weight
- C35H54GdN7O15 · 970.1 g/mol (avg)
- First approval
- Canada, 2026 · United States, 2022 · European Union, 2024
- Also known as
- 2-[3,9-bis[1-carboxylato-4-(2,3-dihydroxypropylamino)-4-oxobutyl]-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]-5-(2,3-dihydroxypropylamino)-5-oxopentanoate;gadolinium(3+)
- Code names
- P-03277
- Brand names
Resolves to
GNRQMLROZPOLDG-UHFFFAOYSA-KSMILES[Gd+3].OCC(O)CNC(=O)CCC(N1CCN(CC2=CC=CC(CN(CC1)C(CCC(=O)NCC(O)CO)C([O-])=O)=N2)C(CCC(=O)NCC(O)CO)C([O-])=O)C([O-])=OWhat you can answer from here — as of August 31, 2026
Which other approved drugs treat the same conditions as Gadopiclenol, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account